Telix Pharmaceuticals (ASX:TLX) Chief Executive Christian Behrenbruch said the company is prioritizing the advancement of its therapeutic pipeline, which includes three pivotal stage trials in prostate, kidney, and brain cancer, by reinvesting earnings, according to a Friday filing with the Australian bourse.
The company also plans to expand its precision medicine growth through label expansion studies and new product launches, per the filing.
Shares rose nearly 8% in midday trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.